MEIS1-mediated transactivation of synaptotagmin-like 1 promotes CXCL12/CXCR4 signaling and leukemogenesis

Meis1 is a TALE-class homeodomain transcription factor that is important in hematopoiesis, vasculogenesis, cardiac development and eye development. Meis1 is also important for Hox functions in myeloid leukemogenesis. However, its functions in leukemogenesis and the significance of its cooperation with Hox have not been clarified..More



Temporarily closed.


Temporarily closed.


Developing safe and effective anti-cancer drugs and treatments

Pathology Project for Molecular Targets

Our aim is to create a novel field of pathology for patients, therapy-oriented pathology.

Cancer Systems Biology

Our goal is to establish novel cancer therapeutic paradigm from robustness-based approach.(

Cancer Genomics

Our aims are to establish personalized medicine and novel bioinformatics methodology.

Protein Engineering

Our aim is to develop cancer diagnosis methods through the use of artificial proteins.

Genetic Diagnosis

We aim to elucidate the mechanisms of breast oncogenesis and establish genetic diagnosis.


We will explore novel approach for cancer treatment by clarifying carcinogenic mechanism.

Cancer Biology

We aim to understand cellular senescence and to elucidate how it is perturbed in cancer.

Experimental Pathology

We aim to elucidate the mechanisms underlying chromosomal instability in cancer cells.

Cell Biology

We investigate carcinogenesis in vivo to develop novel strategies for cancer prevention and treatment.


Our activities involve research on cancer prevention and diagnosis for JFCR Hospital.

Recent Publications

  • M. Koido, N. Haga, A. Furuno, S. Tsukahara, J. Sakurai, Y. Tani, S. Sato and A. Tomida.
    Mitochondrial deficiency impairs hypoxic induction of HIF-1 transcriptional activity and retards tumor growth .
    Oncotarget, in press (2016)
  • Sakha, S., Muramatsu, T., Ueda, K., Inazawa, J.
    Exosomal microRNA miR-1246 induces cell motility and invasion through the regulation of DENND2D in oral squamous cell carcinoma
    Sci Rep, in press (2016)
  • Sakakibara, R., Inamura, K., Tambo, Y., Ninomiya, H., Kitazono, S., Yanagitani, N., Horiike, A., Ohyanagi, F., Matsuura, Y., Nakao, M., Mun, M., Okumura, S., Inase, N., Nishio, M., Motoi, N., Ishikawa, Y.
    EBUS-TBNA as a promising method for the evaluation of tumor PD-L1 expression in lung cancer.
    Clin Lung Cancer, in press (2016)
  • Mori, S., Motoi, N., Ninomiya, H., Matsuura, Y., Nakao, M., Mun, M., Okumura, S., Nishio, M., Morikawa, T., Ishikawa, Y.
    High expression of programmed cell death 1 ligand 1 in lung adenocarcinoma is a poor prognostic factor particularly in smokers and wild-type epidermal growth-factor receptor cases.
    Pathol Int, in press (2016)
  • Nagasawa, I., Kunimasa, K., Tsukahara, S., Tomida, A.
    BRAF-mutated cells activate GCN2-mediated integrated stress response as a cytoprotective mechanism in response to vemurafenib.
    Biochem Biophys Res Commun, in press (2016)